Key Highlights

  • Shares fell 29% to $1.97 following merger announcement
  • Investor reaction reflects concerns over deal structure and dilution
  • All-stock transaction to create combined entity under Scipher name
  • Nebokitug rheumatoid arthritis readout still targeted for first half of 2028
  • Market response highlights skepticism common in biotech reverse mergers

Investors delivered a sharply negative verdict on Chemomab Therapeutics' merger with Scipher Medicine, sending shares down 29% to $1.97 in the session following the announcement. The steep decline stands in contrast to the strategic rationale offered by management, underscoring a familiar pattern in biotech dealmaking: even mergers designed to extend runway and combine complementary assets can trigger outsized selloffs when investors perceive unfavorable exchange terms or dilution risk.

The all-stock structure of the transaction is central to that concern. In reverse-merger-style transactions, existing shareholders of the smaller or weaker-positioned company often end up owning a reduced proportional stake in the combined entity, even when the deal is framed as a strategic combination rather than an acquisition. Without clarity on the exact exchange ratio and resulting ownership split, the market's reflexive response — a steep share-price decline — suggests investors are pricing in meaningful dilution to Chemomab's existing base.

That reaction came despite genuine strategic logic underpinning the deal. The combination pairs Chemomab's lead candidate, nebokitug, with Scipher's AI-driven precision medicine platform, aiming to strengthen the odds of the drug's Phase 2 rheumatoid arthritis trial by better identifying likely responders. The $30 million in committed financing accompanying the merger is also a genuine positive, extending the runway of the combined company into the second half of 2028 and reducing the risk of near-term forced financing at unfavorable terms.

Whether the selloff represents an overreaction or an accurate repricing of dilution risk will likely become clearer once full transaction details, including the exchange ratio and pro forma ownership breakdown, are disclosed in subsequent filings. For now, the market's message is unambiguous: skepticism toward the deal's terms currently outweighs enthusiasm for the strategic combination itself.

Why did Chemomab shares fall sharply on the merger news?

Shares dropped 29% to $1.97 as investors priced in concerns over dilution and deal structure typical of all-stock reverse mergers, despite the strategic rationale behind the combination.

Does the merger change the nebokitug clinical timeline?

No — the combined entity still targets a Phase 2 rheumatoid arthritis data readout in the first half of 2028, supported by $30 million in committed financing.

This article is for informational purposes and does not constitute investment advice.